- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Cantor Fitzgerald behält Übergewichtung für GH Research-Aktie bei | 1 | Investing.com Deutsch | ||
| 27.05. | GH Research PLC - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 15.05. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.05. | GH Research PLC: GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting | 53 | GlobeNewswire (Europe) | DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing... ► Artikel lesen | |
| 08.05. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.05. | GH Research PLC: GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates | 128 | GlobeNewswire (Europe) | Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents... ► Artikel lesen | |
| 03.03. | Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025 | 6 | Insider Monkey | ||
| GH RESEARCH Aktie jetzt für 0€ handeln | |||||
| 01.03. | GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025 | 2 | Insider Monkey | ||
| 27.02. | GH Research PLC - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 27.02. | GH Research PLC: GH Research Reports Full Year 2024 Financial Results and Provides Business Updates | 167 | GlobeNewswire (Europe) | Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate... ► Artikel lesen | |
| 27.02. | GH Research PLC - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 27.02. | GH Research PLC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 26.02. | Stifel raises GH Research stock target to $32 on strong trial data | 1 | Investing.com | ||
| 13.02. | Cantor Fitzgerald sets GH Research stock Overweight, $14 target | 3 | Investing.com | ||
| 06.02. | GHRS Stock Rallies 55% in a Week: Here's What You Should Know | 3 | Zacks | ||
| 05.02. | GH Research prices $150M stock offering | 4 | Seeking Alpha | ||
| 05.02. | GH Research Prices Public Offering Of 10 Mln Shares At $15.00/shr | 2 | RTTNews | ||
| 05.02. | GH Research PLC: GH Research Announces Pricing of $150 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 04.02. | GH Research leaps on psychedelic data in depression | - | pharmaphorum | ||
| 04.02. | H.C. Wainwright maintains buy on GH Research stock, $40 target | 2 | Investing.com |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
| VALNEVA | 2,732 | -0,15 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH 03.06.2025 / 14:27 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den... ► Artikel lesen | |
| BIOFRONTERA | 2,500 | 0,00 % | Biofrontera sichert Patent für Ameluz-Formulierung bis 2043 | ||
| BIOGEN | 116,70 | -0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
| ILLUMINA | 72,45 | -0,10 % | Does Illumina (ILMN) Have Good Long-Term Growth Prospects? | ||
| NANOREPRO | 1,675 | -1,18 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.05.2025 / 14:00... ► Artikel lesen | |
| OCUGEN | 0,917 | -0,97 % | Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen... ► Artikel lesen | |
| VAXART | 0,364 | +2,42 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders | ||
| CYTODYN | 0,282 | 0,00 % | CytoDyn Inc.: CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer | VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential... ► Artikel lesen | |
| IMMUNIC | 0,698 | +1,16 % | EQS-News: Immunic AG: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining... ► Artikel lesen | |
| CEL-SCI | 2,380 | +1,28 % | Pre-market Movers: Navitas Semiconductor, Longevity Health, CEL-SCI, Hyperscale Data, Sunrun | PHILADELPHIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.35 A.M. ET).In the Green Navitas Semiconductor Corporation (NVTS) is... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 8,892 | +0,47 % | Cathie Wood's ARK buys Guardant Health, sells Adaptive Biotechnologies stock | ||
| BLUEPRINT MEDICINES | 112,00 | -0,18 % | Sanofi erwirbt Blueprint Medicines für bis zu 9,5 Milliarden Dollar | DJ Sanofi erwirbt Blueprint Medicines für bis zu 9,5 Milliarden Dollar
Von Adria Calatayud
DOW JONES--Sanofi will Blueprint Medicines, ein auf seltene immunologische Erkrankungen spezialisiertes... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,542 | -5,90 % | MustGrow Biologics Corp.: MustGrow Announces Record Q1-2025 Results: $3.8 Million Revenue, 14.3% Gross Profit Margin, $4.4 Million in Cash and Inventory | Register/View Here: https://us02web.zoom.us/webinar/register/6217478678603/WN_h8uMVWINQsmS3HWF8K59WgPlease join/register at least 5 minutes prior to the call.Questions emailed to info@mustgrow.ca will... ► Artikel lesen | |
| GENPREX | 1,820 | -100,00 % | Genprex, Inc.: Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting | Both REQORSA Alone and in Combination with LUMAKRAS® Demonstrated Robust Anti-Tumor Effects in Ras Inhibitor Resistant Non-Small Cell Lung Cancer
AUSTIN, Texas... ► Artikel lesen |
GH RESEARCH PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,100 (+0,95 %) liegt der Kurs bei 10,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GH RESEARCH PLC finden Sie auf Wallstreet Online.